Krystal Biotech Touts Positive Results for Gene Therapy Treating Tissue Disease

Krystal Biotech has released positive phase 3 results for its gene therapy Vyjuvek (beremagene geperpavec) developed to treat dystrophic epidermolysis bullosa (EB), an inherited connective tissue disease.

The late-stage study showed that Vyjuvek, administered topically, induced 67 percent complete wound healing vs. 22 percent in the placebo cohort at six months.

Krystal said Vyjuvek is the first gene therapy developed to treat dystrophic EB that has successfully completed a double-blinded phase 3 trial. The company plans to use the trial results to support an FDA biologics license application submission during the first half of next year.